BCL-2 protein family: attractive targets for cancer therapy
- Author(s)
- Kaloni, D; Diepstraten, ST; Strasser, A; Kelly, GL;
- Details
- Publication Year 2022-11-07,Volume 28,Issue #1-2,Page 20-38
- Journal Title
- Apoptosis
- Abstract
- Acquired resistance to cell death is a hallmark of cancer. The BCL-2 protein family members play important roles in controlling apoptotic cell death. Abnormal over-expression of pro-survival BCL-2 family members or abnormal reduction of pro-apoptotic BCL-2 family proteins, both resulting in the inhibition of apoptosis, are frequently detected in diverse malignancies. The critical role of the pro-survival and pro-apoptotic BCL-2 family proteins in the regulation of apoptosis makes them attractive targets for the development of agents for the treatment of cancer. This review describes the roles of the various pro-survival and pro-apoptotic members of the BCL-2 protein family in normal development and organismal function and how defects in the control of apoptosis promote the development and therapy resistance of cancer. Finally, we discuss the development of inhibitors of pro-survival BCL-2 proteins, termed BH3-mimetic drugs, as novel agents for cancer therapy.
- Publisher
- Springer
- Keywords
- Apoptosis; BCL-2 protein family; BH3-mimetic drugs; BH3-only proteins; Pro-apoptotic BCL-2 family members; Pro-survival BCL-2 proteins
- Research Division(s)
- Blood Cells And Blood Cancer
- PubMed ID
- 36342579
- Publisher's Version
- https://doi.org/10.1007/s10495-022-01780-7
- Open Access at Publisher's Site
https://doi.org/10.1007/s10495-022-01780-7- NHMRC Grants
- NHMRC/GNT1113133, NHMRC/GNT1116937, NHMRC/GNT1143105, NHMRC/GNT 2002618, NHMRC/GNT2001201,
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2022-11-08 02:27:10
Last Modified: 2023-10-27 09:25:09